Please login to the form below

Not currently logged in
Email:
Password:

Ipsen stake in Inspiration reaches 41 per cent as haemophilia trial starts

Enrolment of first patient into trial of OBI-1 triggers $25m purchase by Ipsen of Inspiration's stock

France-based Ipsen has expanded its stake in US partner Inspiration Biopharmaceuticals following the start of phase III trials of their candidate drug for haemophilia A.

The enrolment of the first patient into the trial of the OBI-1 (recombinant porcine Factor VIII) product triggers a $25m purchase by Ipsen of Inspiration's stock, boosting its stake in the US firm to almost 41 per cent.

The study is the second of two phase III trials scheduled for OBI-1, which is designed to treat patients with congenital haemophilia A who have developed inhibitory antibodies against human Factor VIII replacement therapies. It will gauge the efficacy of OBI-1 in the treatment of severe bleeding episodes.

An earlier phase III study, initiated in November 2010, is looking at the role of OBI-1 in patients with acquired haemophilia A who have developed inhibitors. Preliminary results from this trial were presented in July at the International Society on Thrombosis and Haemostasis (ISTH) annual meeting.

"Currently, patients suffering from haemophilia A who have developed inhibitors have limited therapeutic options," said Marc de Garidel, Ipsen's chairman and chief executive.

Ipsen and Inspiration forged an alliance at the beginning of 2010 which involved the cross-licensing of OBI-1 and Innovation's IB1001, a recombinant factor IX product being developed for the treatment and prevention of bleeding in individuals with haemophilia B.

At the time, Ipsen took a 20 per cent stake in the US firm for $85m, with an option to increase that to 47 per cent, based on milestones achieved in the clinical development programmes for the two drugs. All told, the value of the collaboration could reach $174m.

Last month, Inspiration had its marketing application for IB001 accepted by the European Medicines Agency (EMA), prompting a $35m payment from Ipsen.

In August, the two companies signed a new agreement to create a haemophilia business unit within Ipsen's existing European commercial operations, which will be the exclusive commercial agent for all products marketed under the Inspiration brand in Europe, including IB1001.

29th November 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Genetic Digital

We help healthcare, pharma & medical device organisations use web and mobile technologies to effectively connect patients and healthcare professionals....

Latest intelligence

NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE
NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE The bold digital clock featured on the EUGDPR (EU General Data Protection Regulation)1 website indicates – to the second...
Health knowledge: Why is it so important?
Health knowledge plays an important role in population health, but by itself is rarely enough to prompt a change in the behaviours that cause the risks....
Personas: a top tool for personalising pharma marketing campaigns
Healthcare customers are calling for greater personalisation in care from providers. Here, we explain why personas are the top tool for ensuring your brand meets this need efficiently and effectively....

Infographics